Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen

Documenti analoghi

• A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer()
  di: Wang, Gen, et al.
  Pubblicazione: (2017)
• A Potential Prognostic Long Noncoding RNA Signature to Predict Recurrence among ER-positive Breast Cancer Patients Treated with Tamoxifen
  di: Wang, Kang, et al.
  Pubblicazione: (2018)
• Expression signature of ten genes predicts the survival of patients with estrogen receptor positive-breast cancer that were treated with tamoxifen
  di: Huang, He, et al.
  Pubblicazione: (2018)
• Evaluation of the ability of adjuvant tamoxifen‐benefit gene signatures to predict outcome of hormone‐naive estrogen receptor‐positive breast cancer patients treated with tamoxifen in the advanced setting
  di: Sieuwerts, Anieta M., et al.
  Pubblicazione: (2014)
• HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
  di: Li, Shuai, et al.
  Pubblicazione: (2020)